Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Gilead Sciences, Inc
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A long-term study to follow patients infected with chronic Hepatitis C who did not achieve a cure following treatment in a Gilead clinical trial
To evaluate HCV viral sequences and the persistence of treatment emergent viral resistant mutations in subjects who fail to achieve SVR after treatment with an oral antiviral containing regimen in a G...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B. Studio randomizzato, in doppio cieco, controllato per la valutazione di Tenofovir DF verso Adefovir Dipivoxil nel trattamento dell'epatite B cronica HBeAg-positiva
To compare the efficacy, the safety and tolerability of tenofovir DF 300 mg QD versus adefovir dipivoxil 10 mg QD for the treatment of HBeAg positive chronic hepatitis B. Confrontare l'efficacia...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A clinical research study to see how six medications that are approved for the treatment of HIV-1 infection affect the kidneys. The six approved medications are Stribild, Truvada, Atripla, Reyataz, Norvir, and Kivexa. Both the patient and the investigator will know which medication the patient is receiving. This is a randomised (by chance, like the flip of a coin) study Ensayo clínico para ver cómo afectan a los riñones seis medicamentos actualmente autorizados para el tratamiento de la infección por el VIH-1. Los seis medicamentos son Stribild, Truvada, Atripla, Reyataz, Norvir, y Kivexa. Tanto el investigador como el paciente sabrán qué medicación está tomando el paciente. Es un estudio aleatorizado (asignación al azar, como tirando una moneda al aire)
To assess glomerular function before and during administration of Stribild (STB) or a regimen containing Tenofovir disoproxil fumarate (TDF) without Cobisistat (COBI) as ritonavir-boosted atazanavir p...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A study to optimize the dose of Idelalisib in Follicular Lymphoma
To optimize the safety and efficacy of chronic administration of idelalisib in subjects with follicular lymphoma (FL) who are randomized to treatment with idelalisib at 150 mg twice daily (BID) or 100...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A trial investigating the safety and efficacy of the drug combination Sofosbuvir/Velpatasvir/GS-9857 for 12 weeks against Sofosbuvir/Velpatasvir for 12 weeks for subjects with hepatitis C
To determine the efficacy of treatment with sofosbuvir (SOF)/velpatasvir (VEL)/GS-9857 fixed dose combination (FDC) for 12 weeks and of SOF/VEL FDC for 12 weeks as measured by the proportion of subjec...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
The purpose of this study is to evaluate if F/R/TAF works as well as Atripla. It is also to see if F/R/TAF will maintain the control of your HIV-1 infection when compared to Atripla. Safety, how well your body accepts the drug, will be evaluated
To evaluate the non-inferiority of switching to the FTC/RPV/TAF FDC as compared to continuing EFV/FTC/TDF FDC in virologically suppressed HIV-1 infected subjects as determined by maintaining HIV-1 RNA...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
An international study to assess the safety and efficacy of a combination of new investigational drugs in hepatitis C virus infected patients with advanced liver disease or require treatment after kidney transplantation
The primary objectives of this study are as follows: • To determine the antiviral efficacy of LDV/SOF FDC as measured by the proportion of subjects who attain SVR at 12 weeks after discontinuation of...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
- To evaluate the steady state pharmacokinetics (PK) for elvitegravir and tenofovir alafenamide and confirm the dose of the E/C/F/TAF single tablet regimen (STR) in HIV-1 infected, antiretroviral (AR...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
An international study to assess the safety and efficacy of new investigational drugs and standard of care in patients with chronic hepatatis C virus infection
To determine the efficacy of PSI-7977 in combination with RBV administered for 12 weeks compared with PEG/RBV administered for 24 weeks in treatment-naïve patients with HCV genotype 2 or 3 as assessed...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 5 ans
A study with GS-7977 and Ribavirin in Hepatitis C patients with cirrhosis and portal hypertension Estudio con GS-7977 y ribavirina en pacientes con Hepatitis C con cirrosis e hipertensión portal
To determine the antiviral efficacy of combination therapy with GS-7977 + Ribavirin (RBV) for 24 weeks in compensated and decompensated chronic HCV subjects as measured by sustained virologic response...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
3
4
5
6
7
8
9
10
11
12
Next